NASDAQ:ATHA Athira Pharma Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.42 +0.20 (+6.21%) (As of 07/5/2022 03:59 PM ET) Add Compare Share Today's Range$3.23▼$3.5050-Day Range$2.74▼$11.0152-Week Range$2.53▼$16.65Volume62,177 shsAverage Volume2.12 million shsMarket Capitalization$128.73 millionP/E RatioN/ADividend YieldN/APrice Target$27.60 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Athira Pharma MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside707.0% Upside$27.60 Price TargetShort InterestBearish9.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 8 Articles This WeekInsider TradingAcquiring Shares$836,100 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.67) to ($3.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.42 out of 5 starsMedical Sector138th out of 1,428 stocksBiological Products, Except Diagnostic Industry18th out of 218 stocks 4.2 Analyst's Opinion Consensus RatingAthira Pharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.60, Athira Pharma has a forecasted upside of 707.0% from its current price of $3.42.Amount of Analyst CoverageAthira Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.03% of the float of Athira Pharma has been sold short.Short Interest Ratio / Days to CoverAthira Pharma has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Athira Pharma has recently increased by 6.80%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAthira Pharma does not currently pay a dividend.Dividend GrowthAthira Pharma does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATHA. Previous Next 3.1 News and Social Media Coverage News SentimentAthira Pharma has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Athira Pharma this week, compared to 4 articles on an average week.Search Interest10 people have searched for ATHA on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Athira Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Athira Pharma insiders have bought 2,004.83% more of their company's stock than they have sold. Specifically, they have bought $836,100.00 in company stock and sold $39,723.00 in company stock.Percentage Held by Insiders14.90% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.76% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Athira Pharma are expected to decrease in the coming year, from ($2.67) to ($3.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Athira Pharma is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Athira Pharma is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAthira Pharma has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ATHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address About Athira Pharma (NASDAQ:ATHA) StockAthira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.Read More ATHA Stock News HeadlinesJuly 2, 2022 | americanbankingnews.comAthira Pharma, Inc. (NASDAQ:ATHA) Director Perceptive Advisors Llc Purchases 270,000 Shares of StockJuly 2, 2022 | americanbankingnews.comHans Moebius Purchases 10,000 Shares of Athira Pharma, Inc. (NASDAQ:ATHA) StockJune 28, 2022 | americanbankingnews.comAthira Pharma, Inc. (NASDAQ:ATHA) Receives $21.75 Average Target Price from BrokeragesJune 28, 2022 | americanbankingnews.comJefferies Financial Group Weighs in on Athira Pharma, Inc.'s Q2 2023 Earnings (NASDAQ:ATHA)June 26, 2022 | americanbankingnews.comMark James Litton Sells 7,960 Shares of Athira Pharma, Inc. (NASDAQ:ATHA) StockJune 26, 2022 | americanbankingnews.comAthira Pharma (NASDAQ:ATHA) Cut to Hold at Stifel NicolausJune 25, 2022 | americanbankingnews.comAthira Pharma, Inc. (NASDAQ:ATHA) COO Rachel Lenington Sells 4,193 SharesJune 25, 2022 | americanbankingnews.comAthira Pharma (NASDAQ:ATHA) Rating Lowered to Hold at Stifel NicolausJune 24, 2022 | americanbankingnews.comAthira Pharma (NASDAQ:ATHA) Downgraded by JMP Securities to Market PerformJune 24, 2022 | americanbankingnews.comAthira Pharma (NASDAQ:ATHA) Rating Lowered to Hold at Jefferies Financial GroupJune 23, 2022 | markets.businessinsider.com4 Analysts Have This to Say About Athira PharmaJune 23, 2022 | seekingalpha.comAthira Pharma downgraded at JMP after Alzheimer’s setbackJune 22, 2022 | finance.yahoo.comAthira Pharma Shares Fall To 52-Week Low - Read WhyJune 22, 2022 | seekingalpha.comAthira Pharma crashes 67% as lead asset fails in Alzheimer’s trialJune 22, 2022 | seekingalpha.comAthira Pharma: The Market Is Missing A Potential New Alzheimer's DrugJune 22, 2022 | markets.businessinsider.comWhy Athira Pharma Stock Is PlungingJune 22, 2022 | finance.yahoo.comAthira Pharma stock loses two-thirds of its value after study of Alzheimer's treatment misses primary endpointJune 22, 2022 | finance.yahoo.comAthira Pharma's stock plummets after disappointing drug trial resultsJune 22, 2022 | finance.yahoo.comAthira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s DiseaseJune 7, 2022 | finance.yahoo.comAthira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology ResearchMay 22, 2022 | finance.yahoo.comWhat Kind Of Investors Own Most Of Athira Pharma, Inc. (NASDAQ:ATHA)?May 21, 2022 | morningstar.comShareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting | MorningstarMay 19, 2022 | finance.yahoo.comShareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual MeetingMay 19, 2022 | finance.yahoo.comShareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual MeetingMay 17, 2022 | morningstar.comAthira Issues Statement in Response to Richard A. Kayne’s Suspension of His Proxy Contest | MorningstarSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATHA CUSIPN/A CIK1620463 Webathira.com Phone425-620-8501FaxN/AEmployees34Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today7/05/2022Next Earnings (Estimated)8/15/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$27.60 High Stock Price Forecast$51.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+707.0%Consensus RatingHold Rating Score (0-4)2.33333333333333 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,850,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.45% Return on Assets-19.81% Debt Debt-to-Equity RatioN/A Current Ratio28.42 Quick Ratio28.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.60 per share Price / Book0.40Miscellaneous Outstanding Shares37,640,000Free Float32,028,000Market Cap$128.73 million OptionableNot Optionable Beta3.92 Athira Pharma Frequently Asked Questions Should I buy or sell Athira Pharma stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athira Pharma in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Athira Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATHA, but not buy additional shares or sell existing shares. View analyst ratings for Athira Pharma or view top-rated stocks. What is Athira Pharma's stock price forecast for 2022? 6 brokerages have issued 1-year target prices for Athira Pharma's stock. Their ATHA stock forecasts range from $5.00 to $51.00. On average, they predict Athira Pharma's share price to reach $27.60 in the next year. This suggests a possible upside of 707.0% from the stock's current price. View analysts' price targets for Athira Pharma or view top-rated stocks among Wall Street analysts. How has Athira Pharma's stock price performed in 2022? Athira Pharma's stock was trading at $13.03 at the beginning of 2022. Since then, ATHA shares have decreased by 73.8% and is now trading at $3.42. View the best growth stocks for 2022 here. When is Athira Pharma's next earnings date? Athira Pharma is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022. View our earnings forecast for Athira Pharma. How were Athira Pharma's earnings last quarter? Athira Pharma, Inc. (NASDAQ:ATHA) issued its quarterly earnings results on Thursday, May, 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.01. View Athira Pharma's earnings history. Who are Athira Pharma's key executives? Athira Pharma's management team includes the following people: Dr. Mark J. Litton M.B.A., MBA, Ph.D., Pres, CEO & Director (Age 54, Pay $726.32k)Ms. Rachel P. Lenington M.B.A., Chief Operating OfficerMr. Mark F. Worthington J.D., Gen. Counsel & Corp. Sec.Ms. Glenna K. Mileson, Chief Financial Officer (Age 63)Mr. Robert Renninger, Director of Accounting & ReportingMs. Julie Rathbun, Head of Investor RelationsDr. Kevin Church Ph.D., Exec. VP of Research (Age 37) Who are some of Athira Pharma's key competitors? Some companies that are related to Athira Pharma include Immunovant (IMVT), Monte Rosa Therapeutics (GLUE), Brickell Biotech (BBI), C4 Therapeutics (CCCC), Aura Biosciences (AURA), ADMA Biologics (ADMA), Kodiak Sciences (KOD), Aerie Pharmaceuticals (AERI), HilleVax (HLVX), Adagio Therapeutics (ADGI), Humacyte (HUMA), bluebird bio (BLUE), Forma Therapeutics (FMTX), MeiraGTx (MGTX) and Caribou Biosciences (CRBU). View all of ATHA's competitors. What other stocks do shareholders of Athira Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Athira Pharma investors own include GW Pharmaceuticals (GWPH), Intel (INTC), Lumentum (LITE), NIO (NIO), NVIDIA (NVDA), Boeing (BA), Alibaba Group (BABA), Beyond Meat (BYND), Delta Air Lines (DAL) and Extreme Networks (EXTR). When did Athira Pharma IPO? (ATHA) raised $160 million in an initial public offering on Friday, September 18th 2020. The company issued 10,000,000 shares at $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel served as the underwriters for the IPO and JMP Securities was co-manager. What is Athira Pharma's stock symbol? Athira Pharma trades on the NASDAQ under the ticker symbol "ATHA." How do I buy shares of Athira Pharma? Shares of ATHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Athira Pharma's stock price today? One share of ATHA stock can currently be purchased for approximately $3.42. How much money does Athira Pharma make? Athira Pharma (NASDAQ:ATHA) has a market capitalization of $128.73 million. The company earns $-54,850,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. How many employees does Athira Pharma have? Athira Pharma employs 34 workers across the globe. How can I contact Athira Pharma? The official website for Athira Pharma is athira.com. The company can be reached via phone at 425-620-8501 or via email at ir@athira.com. This page (NASDAQ:ATHA) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
